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ABSTRACT  
 
We evaluated for the first time adverse health outcomes (AHOs) among U.S. testicular 
cancer survivors (TCS) given chemotherapy (n=381) vs. surgery-only patients (n=98) 
managed at a single institution, accounting for non-treatment-related risk factors to 
delineate chemotherapy’s impact. Chemotherapy consisted largely of bleomycin-
etoposide-cisplatin (BEP) administered in 3 or 4 cycles (BEPX3, n=235; BEPX4, n=82). 
Incidence of ≥3 AHOs was lowest in surgery-only TCS and increased with BEPX3, 
BEPX4 and other cisplatin-based regimens (12.2%, 40.8%, 52.5%, 54.8%; P<0.0001). 
Multivariate modeling assessed associations of risk factors and treatment with hearing 
impairment, tinnitus, peripheral neuropathy, and Raynaud phenomenon. Risk for each 
AHO significantly increased with both increasing chemotherapy burden (P<0.0001) and 
selected modifiable risk factors (P<0.05): hypertension (OR=2.40) and noise exposure 
(OR≥2.3) for hearing impairment; noise exposure for tinnitus (OR≥1.69); peripheral 
vascular disease for neuropathy (OR=8.72), and current smoking for Raynaud 
phenomenon (OR=2.41). Clinicians should manage modifiable risk factors for AHOs 
among TCS. 
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BRIEF COMMUNICATION  
 
 Testicular cancer (TC) is the most common cancer in men aged 18-39 years (1). 
Since cisplatin-based chemotherapy was introduced in the 1970s (2), the overall 5-year 
relative survival rate is over 95% (3).  As a result, one in 600 U.S. men is a TC survivor 
(TCS), representing a growing need to evaluate the subsequent development of 
adverse health outcomes (AHOs). Nonetheless, the few single-institution investigations 
of U.S. TCS (4,5,6,78) have been limited in scope, generally either not addressing 
AHOs (5,7,8) or evaluating fewer than five conditions (6). Additionally, only Oh et al. (6) 
included a control group of TCS managed with surgical approaches alone, but 
examined only four AHOs.  
In view of these gaps, our goal was study AHOs among U.S. TCS after 
contemporary cisplatin-based chemotherapy compared with a surgery-only cohort. The 
study was IRB-approved at Indiana University. Eligible TCS had a histologic/serological 
germ cell tumor (GCT) diagnosis at ≤55 years; all administered treatment/management 
was completed ≥1 year prior to enrollment. All participants were disease-free at routine 
follow-up and completed AHO-focused health questionnaires. AHO definitions and 
statistical methods are provided in Supplementary Methods. Two-sided P <0.05 defined 
statistical significance.  
 Overall, 479 patients were evaluated (Table 1). Chemotherapy (n=381) consisted 
largely of 3 or 4 cycles of bleomycin, etoposide, and cisplatin (BEPX3, n=235; BEPX4, 
n=82), with 64 patients receiving other cisplatin-based chemotherapy regimens 
(OtherPlat). Median cumulative cisplatin doses were 300 mg/m2 (BEPx3) and 400 
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mg/m2 (BEPx4 and OtherPlat). 98 patients were managed only surgically. No patient 
received radiotherapy. 
 Median age at evaluation (overall=38.3 years) and median time since 
chemotherapy/surgery completion (overall=4.1 years) were similar between groups. 
Surgery-only patients had a smaller percentage of nonseminomatous histology 
compared to chemotherapy-treated TCS receiving BEPx3, BEPx4, and OtherPlat 
(43.3% vs. 77.6%, 92.6%, 77.0%, respectively; P<0.0001) and were more likely to have 
primary testicular GCT (100% vs. 88.4%, 67.9%, 63.9%, respectively; P<0.0001). Other 
clinical characteristics, physical examination results, and health behaviors were similar 
between  groups, but more surgery-only TCS reported the absence of noise exposure 
than did chemotherapy-treated TCS (61.2% vs. 51.1%, 37.5%, 43.5%, respectively; 
P=0.0073).  Median number of AHOs increased from 1 (range: 0-11) after surgery-only 
to 2 (range: 0-10) after BEPx3 and 3 (range:0-9) after BEPx4 and OtherPlat. Fewer 
TCS had ≥3 AHOs after surgery-only (12.2%) than after BEPX3 (40.8%), BEPX4 
(52.5%), and OtherPlat (54.8%) (P<0.0001). Significant differences between surgery-
only, BEPX3, BEPX4 and OtherPlat were observed for the following AHOs (each 
P<0.05): hearing impairment (11.5%, 36.0%, 41.8%, 45.9%); tinnitus (16.3%, 39.3%, 
43.9%, and 50.0%); peripheral neuropathy (4.1%, 27.8%, 33.8%, 46.9%); hypertension 
(0%, 15.7%, 15.0%, 15.0%); Raynaud phenomenon (2.0%, 20.3%, 29.6%, 20.6%); and 
balance/vertigo/dizziness (6.1%, 11.0%, 19.5%, 14.3%). For cardiovascular disease 
(CVD), differences were of borderline significance (1.0%, 5.6%, 9.9%, 7.9%; P=0.0648). 
Table 2 shows the results of multivariate modeling for selected AHOs. TCS given 
BEPX3, BEPX4, and OtherPlat experienced significant tinnitus excesses (OR=3.0, 3.71, 
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and 3.99 [P=0.0005 each]), with risk increased by 1.44-fold (P<0.0001) for each 100 
mg/m2 of cisplatin. Prior work-related (OR=1.69, P=0.0426), non-work-related (OR=2.1, 
P=0.0399) and cumulative (OR=2.13, P=0.0078) noise exposure were associated with 
significantly increased 2-fold tinnitus risks, but no interaction with cisplatin dose existed 
(P=0.5892).  
Hearing loss increased significantly with increasing age at clinical evaluation 
(OR=1.16 per 5 years, P=0.0259), hypertension (OR=2.40, P=0.0101), and in each 
chemotherapy group (P<0.01 each). With each 100 mg/m2 increase in cisplatin, hearing 
loss increased by 1.4-fold (P=0.0002). Work-related (OR=2.30, P=0.0033), non-work-
related (OR=3.64, P=0.0009), and cumulative (OR=2.75, P=0.0012) noise exposure 
conferred increased hearing loss, but no interaction with cisplatin dose existed 
(P=0.3672).   
Raynaud phenomenon was increased 12-fold (P=0.0009) and 21-fold (P<0.0001) 
following BEPx3 and BEPx4, respectively, and 12-fold after OtherPlat (P=0.0018). Risk 
increased with increasing bleomycin dose (OR=1.36 per 90,000 IU, P=0.0016). Current 
smoking was associated with significantly increased 2.4-fold risks.  
Peripheral neuropathy was increased by 9-, 13-, and 18-fold, respectively, after 
BEPx3, BEPx4, and OtherPlat (P<0.0001 each). Increasing age at assessment 
(OR=1.23 per 5 years, P=0.0033), higher cumulative cisplatin dose (OR=1.75 per 100 
mg/m2, P<0.0001) and peripheral vascular disease (OR=8.72, P=0.0010) were 
associated with higher neuropathy risks.  
Our study investigates for the first time the prevalence and risk factors for 
chemotherapy-related AHOs in U.S. TCS, with surgery-only patients as the control 
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group. We took into account previously identified AHO-specific risk factors, thus, 
furthering our understanding of the specific impact of chemotherapy. Risk of treatment-
related AHOs increased proportionately with increasing chemotherapy burden. 
Importantly, modifiable risk factors were also associated with AHOs even when 
controlled for chemotherapy.  
It is noteworthy that even after a short median follow-up, about 1 in 7 TCS in 
each chemotherapy group had hypertension compared with no cases after surgery-only 
(P=0.0007). A similar trend of borderline significance was noted for CVD.  
 Major strengths of our study are that all TCS were managed at one large, well-
established U.S. institution. However, AHOs were largely self-reported without baseline 
data pre-therapy. Cross-sectional designs have potential inherent limitations and do not 
permit causal inference, although prospective follow-up is planned. Although the control 
group (surgery-only patients) had a lower disease burden initially than did 
chemotherapy-treated TCS, no TCS had active disease at the time of study enrollment. 
We cannot rule out, however, any potential influence of initial disease burden on AHO 
development.  
Nonetheless, we provide for the first time estimates of the magnitude of AHOs 
associated with current chemotherapy in U.S. TCS compared with surgery-only 
patients. This may potentially guide clinical decision-making, such as recommending 
surgical approaches with primary retroperitoneal lymph node dissection (RPLND) in 
patients with low-bulk stage II disease in an attempt to avoid chemotherapy-related 
AHOs. Future studies should address AHO incidence when adjuvant chemotherapy is 
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applied in early stage disease, or in guiding decisions regarding primary RPLND vs. 
chemotherapy in early stage II disease.  
The incidence of several AHOs (e.g., hypertension, CVD) will likely increase with 
the aging process (9). Thus, patients should be encouraged to adopt practices 
consistent with a healthy lifestyle and to avoid noise exposure, ototoxic drugs, and other 
factors that may further impact AHOs. Health care providers should diligently manage 
co-morbidities to minimize the development or exacerbation of AHOs.  
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Table 1: Clinical and Other Characteristics and Adverse Health Outcomes in Testicular Cancer Survivors by Type of Management   
 
Characteristic 
 
 
Treatment regimen  
All patients Surgery BEPx3 BEPx4 
Other 
chemotherapya 
P-Valueb 
Total N =479  N=98 N=235 N=82 N=64  
 
Clinical characteristic 
Age at diagnosis, years       
Median [range] 31.0 [10.0, 56.2] 33.9 [15.4, 56.2] 30.0 [10.0, 53.0] 27.0 [16.0, 49.0] 31.5 [13.0, 55.0] 0.0092 
Age at clinical evaluation, 
years      
 
Median [range] 38.3 [18.3, 74.5] 39.0 [20.2, 62.3] 38.4 [18.3, 74.5] 36.3 [20.1, 71.3] 40.6 [20.8, 71.1] 0.2468 
Category      0.3384 
   <20 years 3 (0.6%) 0 3 (1.3%) 0 0  
   20-29 years 101 (21.1%) 20 (20.4%) 47 (20.0%) 21 (25.6%) 13 (20.3%)  
   30-39 years 169 (35.3%) 35 (35.7%) 84 (35.7%) 32 (39.0%) 18 (28.1%)  
   40-49 years 135 (28.2%) 30 (30.6%) 65 (27.7%) 23 (28.0%) 17 (26.6%)  
   50+ years 71 (14.8%) 13 (13.3%) 36 (15.3%) 6 (7.3%) 16 (25.0%)  
Stage of germ cell tumor at 
diagnosisc 
     <0.0001 
I 190 (40.9%) 88 (90.7%) 82 (36.1%) 6 (7.4%) 14 (23.3%)  
II 173 (37.2%) 9 (9.3%) 110 (48.5%) 32 (38.3%) 23 (38.3%)  
III 102 (21.9%) 0 35 (15.4%) 44 (54.3%) 23 (38.3%)  
Histologic typed 
     
<0.0001 
Seminoma 127 (27.0%) 55 (56.7%) 52 (22.4%) 6 (7.4%) 14 (23.0%)  
Nonseminoma 344 (73.0%) 42 (43.3%) 180 (77.6%) 75 (92.6%) 47 (77.0%)  
Sitee 
     
<0.0001 
Testis 397 (84.1%) 98 (100.0%) 205 (88.4%) 55 (67.9%) 39 (63.9%)  
Extragonadal 75 (15.9%) 0 27 (11.6%) 26 (32.1%) 22 (36.1%)  
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Cisplatin-based chemotherapy      <0.0001 
BEPf 329 (68.7%) 0 235 (100.0%) 82 (100.0%) 12 (18.8%)  
EPg 20 (4.2%) 0 0 0 20 (31.3%)  
None 98 (20.5%) 98 (100.0%) 0 0 0  
Otherh 32 (6.7%) 0 0 0 32 (50.0%)  
Cumulative dose of cisplatin, 
mg/m2 
      
Median [range] 300 [0, 700] 0 [0, 0] 300 [276, 334] 400 [370, 414] 400 [198, 700] <0.0001 
Category      <0.0001 
   0 98 (20.5%) 98 (100.0%) 0 0 0  
   < 300 25 (5.2%) 0 16 (6.8%) 0 9 (14.1%)  
   300 216 (45.1%) 0 212 (90.2%) 0 4 (6.3%)  
   301-399 28 (5.8%) 0 7 (3.0%) 13 (15.9%) 8 (12.5%)  
   400 95 (19.8%) 0 0 62 (75.6%) 33 (51.6%)  
   >400 17 (3.5%) 0 0 7 (8.5%) 10 (15.6%)  
Cumulative dose of bleomycin, 
IU 
      
Median [range] 270,000 
[0.0,630,000] 
0.0 [0.0, 0.0] 270,000 
[90,000, 
270,000] 
360,000 [0.0, 
360,000] 
0.0 [0.0, 
630,000] 
<0.0001 
Category      <0.0001 
   0 143 (29.9%) 98 (100.0%) 0 2 (2.4%) 43 (67.2%)  
   >0-180,000 27 (5.6%) 0 8 (3.4%) 8 (9.8%) 11 (17.2%)  
   181,000-270,000 254 (53.0%) 0 227 (96.6%) 22 (26.8%) 5 (7.8%)  
   271,000-360,000 52 (10.9%) 0 0 50 (61.0%) 2 (3.1%)  
   360,000+ 3 (0.6%) 0 0 0 3 (4.7%)  
Retroperitoneal lymph node 
dissectioni 
     <0.0001 
No 303 (64.3%) 80 (81.6%) 157 (68.6%) 30 (37.0%) 36 (57.1%)  
Yes 168 (35.7%) 18 (18.4%) 72 (31.4%) 51 (63.0%) 27 (42.9%)  
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Time from 
chemotherapy/surgery to 
clinical evaluation, years  
      
Median [range] 4.1 [1.0, 34.9] 3.8 [1.0, 30.7] 4.3 [1.0, 25.5] 4.5 [1.0, 34.9] 3.8 [1.0, 25.1] 0.7518 
Category      0.0081 
   <2 years 149 (31.1%) 24 (24.5%) 79 (33.6%) 23 (28.0%) 23 (35.9%)  
   2-5 years 136 (28.4%) 44 (44.9%) 55 (23.4%) 23 (28.0%) 14 (21.9%)  
   6-9 years 70 (14.6%) 15 (15.3%) 36 (15.3%) 13 (15.9%) 6 (9.4%)  
   ≥10 years  124 (25.9%) 15 (15.3%) 65 (27.7%) 23 (28.0%) 21 (32.8%)  
 
Sociodemographic Characteristic 
Race      0.1817 
White 453 (95.0%) 94 (95.9%) 225 (96.2%) 73 (90.1%) 61 (95.3%)  
Non-white 24 (5.0%) 4 (4.1%) 9 (3.8%) 8 (9.9%) 3 (4.7%)  
Marital Statusj      0.4641 
Not married 163 (34.2%) 32 (32.7%) 78 (33.3%) 34 (41.5%) 19 (30.2%)  
Married/Living as married 314 (65.8%) 66 (67.3%) 156 (66.7%) 48 (58.5%) 44 (69.8%)  
Educationk      0.2391 
High school or less 85 (17.8%) 15 (15.3%) 35 (15.0%) 17 (20.7%) 18 (28.1%)  
Some college/College 
Graduate 
296 (62.1%) 62 (63.3%) 146 (62.7%) 51 (62.2%) 37 (57.8%)  
Post-Graduate Level/Other 96 (20.1%) 21 (21.4%) 52 (22.3%) 14 (17.1%) 9 (14.1%)  
Noise Exposurel      0.0073 
None 236 (49.9%) 60 (61.2%) 119 (51.1%) 30 (37.5%) 27 (43.5%)  
Work-related only 111 (23.5%) 22 (22.4%) 60 (25.8%) 17 (21.3%) 12 (19.4%)  
Non-work related only 41 (8.7%) 3 (3.1%) 21 (9.0%) 10 (12.5%) 7 (11.3%)  
Both 85 (18.0%) 13 (13.3%) 33 (14.2%) 23 (28.8%) 16 (25.8%)  
 
Physical Examination Results 
Body mass index, kg/m2m       
Median [range] 28.3 [18.0, 66.6] 28.0 [18.0, 54.3] 28.2 [19.0, 66.6] 28.2 [20.5, 46.1] 29.2 [20.0, 42.0] 0.6641 
Category      0.5166 
   <25 kg/m2 (normal) 105 (22.2%) 24 (25.3%) 54 (23.2%) 16 (19.8%) 11 (17.2%)  
   25-<30 kg/m2 (overweight) 194 (41.0%) 40 (42.1%) 95 (40.8%) 33 (40.7%) 26 (40.6%)  
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   30-<40 kg/m2 (obese) 148 (31.3%) 28 (29.5%) 66 (28.3%) 29 (35.8%) 25 (39.1%)  
   ≥40 kg/m2 (morbidly obese) 26 (5.5%) 3 (3.2%) 18 (7.7%) 3 (3.7%) 2 (3.1%)  
 
Health behavior 
Smoking statusn      0.0938 
Never smoker 284 (59.4%) 60 (61.2%) 150 (64.1%) 45 (54.9%) 29 (45.3%)  
Former smoker 147 (30.8%) 31 (31.6%) 59 (25.2%) 30 (36.6%) 27 (42.2%)  
Current smoker 47 (9.8%) 7 (7.1%) 25 (10.7%) 7 (8.5%) 8 (12.5%)  
Average number of alcoholic 
drinks in past yearo 
     0.3286 
Rarely/never 147 (30.8%) 30 (30.6%) 68 (29.1%) 29 (35.4%) 20 (31.3%)  
≤4/week 182 (38.1%) 46 (46.9%) 90 (38.5%) 23 (28.0%) 23 (35.9%)  
5/week-1/day 92 (19.2%) 16 (16.3%) 44 (18.8%) 20 (24.4%) 12 (18.8%)  
≥2 per day 57 (11.9%) 6 (6.1%) 32 (13.7%) 10 (12.2%) 9 (14.1%)  
Moderate-intensity exercisep      0.0759 
Yes 450 (94.5%) 95 (97.9%) 221 (94.0%) 79 (96.3%) 55 (88.7%)  
No 26 (5.5%) 2 (2.1%) 14 (6.0%) 3 (3.7%) 7 (11.3%)  
Vigorous-intensity exerciseq      0.0664 
Yes 313 (65.8%) 69 (71.1%) 159 (67.7%) 53 (64.6%) 32 (51.6%)  
No 163 (34.2%) 28 (28.9%) 76 (32.3%) 29 (35.4%) 30 (48.4%)  
 
Adverse Health Outcomes  
Total number of adverse health 
outcomes 
      
Median [range] 2.0 [0.0, 11.0] 1.0 [0.0, 11.0] 2.0 [0.0, 10.0] 3.0 [0.0, 9.0] 3.0 [0.0, 9.0] <0.0001 
Category      <0.0001 
   0 82 (17.1%) 33 (33.7%) 41 (17.4%) 5 (6.1%) 3 (4.7%)  
   1 115 (24.0%) 39 (39.8%) 47 (20.0%) 20 (24.4%) 9 (14.1%)  
   2 96 (20.0%) 14 (14.3%) 51 (21.7%) 14 (17.1%) 17 (26.6%)  
   3 66 (13.8%) 7 (7.1%) 32 (13.6%) 15 (18.3%) 12 (18.8%)  
   4 43 (9.0%) 2 (2.0%) 25 (10.6%) 10 (12.2%) 6 (9.4%)  
   5 or more 77 (16.1%) 3 (3.1%) 39 (16.6%) 18 (22.0%) 17 (26.6%)  
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Type of Adverse Health Outcome 
Tinnitusr      <0.0001 
Yes 176 (36.8%) 16 (16.3%) 92 (39.3%) 36 (43.9%) 32 (50.0%)  
No 302 (63.2%) 82 (83.7%) 142 (60.7%) 46 (56.1%) 32 (50.0%)  
Hearing impairments      <0.0001 
Yes 152 (33.2%) 11 (11.5%) 80 (36.0%) 33 (41.8%) 28 (45.9%)  
No 306 (66.8%) 85 (88.5%) 142 (64.0%) 46 (58.2%) 33 (54.1%)  
Peripheral neuropathyt      <0.0001 
Yes 126 (26.5%) 4 (4.1%) 65 (27.8%) 27 (33.8%) 30 (46.9%)  
No 349 (73.5%) 93 (95.9%) 169 (72.2%) 53 (66.3%) 34 (53.1%)  
Ototoxicity and peripheral 
neuropathy 
     <0.0001 
Yes 80 (16.7%) 1 (1.0%) 41 (17.4%) 16 (19.5%) 22 (34.4%)  
No 399 (83.3%) 97 (99.0%) 194 (82.6%) 66 (80.5%) 42 (65.6%)  
Raynaud phenomenonu      <0.0001 
Yes 86 (18.2%) 2 (2.0%) 47 (20.3%) 24 (29.6%) 13 (20.6%)  
No 387 (81.8%) 96 (98.0%) 184 (79.7%) 57 (70.4%) 50 (79.4%)  
Hypogonadism with 
testosterone therapyv 
     0.3004 
Yes 52 (10.9%) 8 (8.2%) 28 (12.0%) 6 (7.4%) 10 (15.9%)  
No 423 (89.1%) 90 (91.8%) 205 (88.0%) 75 (92.6%) 53 (84.1%)  
Erectile dysfunctionw      0.0548 
Yes 67 (14.0%) 8 (8.2%) 30 (12.8%) 15 (18.5%) 14 (21.9%)  
No 410 (86.0%) 89 (91.8%) 205 (87.2%) 66 (81.5%) 50 (78.1%)  
Hypertension and on 
prescription medicationx 
     0.0007 
Yes 57 (12.2%) 0 36 (15.7%) 12 (15.0%) 9 (15.0%)  
No 410 (87.8%) 97 (100.0%) 194 (84.3%) 68 (85.0%) 51 (85.0%)  
Hypercholesterolemia and on 
prescription medicationy 
     0.7902 
Yes 58 (12.2%) 14 (14.3%) 25 (10.8%) 10 (12.2%) 9 (14.1%)  
No 418 (87.8%) 84 (85.7%) 207 (89.2%) 72 (87.8%) 55 (85.9%)  
Cardiovascular diseasez      0.0648 
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Yes 27 (5.7%) 1 (1.0%) 13 (5.6%) 8 (9.9%) 5 (7.9%)  
No 448 (94.3%) 97 (99.0%) 220 (94.4%) 73 (90.1%) 58 (92.1%)  
Peripheral vascular diseaseaa      0.1063 
Yes 19 (4.0%) 1 (1.0%) 8 (3.4%) 5 (6.2%) 5 (8.1%)  
No 455 (96.0%) 97 (99.0%) 225 (96.6%) 76 (93.8%) 57 (91.9%)  
Thromboembolic diseasebb       
    Yes 0 0 0 0 0  
No 474 (100.0%) 98 (100.0%) 233 (100.0%) 81 (100.0%) 62 (100.0%)  
Renal diseasecc      0.1983 
Yes 6 (1.3%) 0 4 (1.7%) 0 2 (3.3%)  
No 462 (98.7%) 97 (100.0%) 227 (98.3%) 80 (100.0%) 58 (96.7%)  
Diabetes and on prescription 
medicationdd 
     0.4671 
Yes 14 (3.0%) 5 (5.1%) 6 (2.6%) 1 (1.2%) 2 (3.2%)  
No 460 (97.0%) 93 (94.9%) 227 (97.4%) 80 (98.8%) 60 (96.8%)  
Thyroid diseaseee      0.6403 
Yes 5 (1.1%) 2 (2.0%) 2 (0.9%) 1 (1.2%) 0  
No 469 (98.9%) 96 (98.0%) 231 (99.1%) 80 (98.8%) 62 (100.0%)  
Problems with 
balance/vertigo/dizzinessff 
     0.0483 
Yes 55 (11.8%) 6 (6.1%) 25 (11.0%) 15 (19.5%) 9 (14.3%)  
No 410 (88.2%) 92 (93.9%) 202 (89.0%) 62 (80.5%) 54 (85.7%)  
Psychotropic prescription 
medication for anxiety and/or 
depressiongg 
     0.1420 
Yes 58 (12.1%) 9 (9.2%) 25 (10.6%) 11 (13.4%) 13 (20.3%)  
No 421 (87.9%) 89 (90.8%) 210 (89.4%) 71 (86.6%) 51 (79.7%)  
Abbreviations: BEPx3, three cycles of bleomycin, etoposide, cisplatin; BEPx4, four cycles of bleomycin, etoposide, cisplatin; EPx4, four cycles of etoposide, cisplatin; RPLND, 
retroperitoneal lymph node dissection 
 
a Patients in this category received BEP chemotherapy other than three or four cycles (n=12), EP chemotherapy (n=20), and other cisplatin-based regimens (n=32). 
b P-value comparisons are based on Chi-square test for categorical variables and Kruskal-Wallis Test (normal approximation) for continuous variables. Missing values were not used 
in the calculation of the p-values.  
c Includes 14 patients for whom the clinical stage was missing. 
d Includes 8 participants with not-otherwise-specified germ cell tumor or unknown histology.  
e Includes 7 patients with primary site not stated.    
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f The standard BEP chemotherapy cycle that all of our patients received consists of bleomycin 30,000 IU days 1,8,15; etoposide 100 mg/m2 days 1 through 5; and cisplatin 20 mg/m2 
days 1 through 5. Includes 12 patients that received BEP other than three or four cycles. 
g The standard dosing and standard EP schedule that all of our patients received consists of etoposide 100 mg/m2 days 1 through 5 and cisplatin 20 mg/m2 days 1 through 5. 
h Includes 32 patients with other cisplatin-based regimens: 11 participants with VIP and 1 with VeIP. Each standard VIP chemotherapy cycle that our patients received consists of 
etoposide 75 mg/m2 days 1 through 5, cisplatin 100 mg/m2 days 1through 5, and ifosfamide 1,200 mg/m2 days 1 through 5. 
i Includes 8 patients for whom retroperitoneal lymph node dissection status was not available. 
j Includes 2 participants with marital status not available. 
k Includes 2 patients for whom education level was not available. 
l Noise exposure data was not available for 6 patients.  
m Includes 6 patients with body mass index information not available.  
n Reported health behavior was not available for 1 patient.  
o Reported health behavior was not available for 1 patient 
p Reported health behavior was not available for 3 patients. 
q Reported health behavior was not available for 3 patients. 
r Category includes 1 patient for whom this outcome was not available. 
s Category includes 21 patients for whom this outcome was not available. 
t Category includes 4 patients for whom this outcome was not available. 
u Category includes 6 patients for whom this outcome was not available. 
v Category includes 4 patients that received bilateral orchiectomy that were not included in the comparison of hypogonadism, but were included elsewhere if the data was available. 
w Category includes 2 patients for whom this outcome was not available. 
x Category includes 12 patients for whom this outcome was not available. 
y Category includes 3 patients for whom this outcome was not available. 
z Category includes 4 patients for whom this outcome was not available. Includes coronary artery disease, heart failure, and cerebrovascular disease (categories not mutually 
exclusive and each category was counted as one AHO). 
aa Category includes 5 patients for whom this outcome was not available. 
bb Category includes 5 patients for whom this outcome was not available. 
cc Category includes 11 patients for whom this outcome was not available. 
dd Category includes 5 patients for whom this outcome was not available. 
ee Category includes 5 patients for whom this outcome was not available. 
ff Category includes 14 patients for whom this outcome was not available. 
gg Participants could report more than one psychotropic medication. 
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Table 2: Logistic Multivariable Regression Analyses of Selected Adverse Health Outcomes (AHO) in 479 Testicular Cancer Survivors  
 
 
Characteristic 
Adverse Health Outcome 
Tinnitus: Yes  
(Ref. = “No") 
Hearing Loss: Yes  
(Ref. = “No”) 
Raynaud Phenomenon: Yes 
(Ref. = “No”) 
Peripheral Neuropathy: Yes  
(Ref. = “No”)  
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P 
 
Clinical Characteristic 
Treatment  
Poverall 
=0.0011 
 
Poverall 
=0.0016 
 
Poverall 
=0.0014 
 
Poverall 
<0.0001 
Surgery only Ref.  Ref.  Ref.  Ref.  
BEPx3a 3.00 (1.61, 5.60) 0.0005 3.52 (1.71, 7.28) 0.0007 11.85 (2.74, 51.29) 0.0009 8.93 (3.04, 26.29) <.0001 
BEPx4 3.71 (1.77, 7.78) 0.0005 3.80 (1.63, 8.85) 0.0020 20.56 (4.49, 94.19) <.0001 12.82 (4.01, 40.94) <.0001 
Other chemotherapyb 3.99 (1.83, 8.72) 0.0005 5.20 (2.14, 12.63) 0.0003 12.04 (2.52, 57.62) 0.0018 17.63 (5.47, 56.83) <.0001 
Age at clinical 
evaluation, per 5 years  
1.11 (0.99, 1.26) 0.0764 1.16 (1.02, 1.33) 0.0259 1.02 (0.87, 1.18) 0.8260 1.23 (1.07, 1.41) 0.0033 
Time since chemo- 
therapy completion, per 
1 year 
1.00 (0.96, 1.04) 0.9636 1.01 (0.97, 1.06) 0.4898 1.02 (0.97, 1.06) 0.5031 0.96 (0.92, 1) 0.0658 
Cumulative dose of 
cisplatin, per 100 mg/m2c  
1.44 (1.22, 1.69) <.0001 1.40 (1.17, 1.66) 0.0002   1.75 (1.41, 2.17) <.0001 
 
Health Behavior 
Smoking status  
Poverall 
=0.4704 
 
Poverall 
=0.6835 
 
Poverall 
=0.0402 
 
Poverall 
=0.5185 
Never smoker Ref  Ref  Ref  Ref  
Former smoker 0.83 (0.52, 1.31) 0.4261 0.81 (0.49, 1.33) 0.4002 0.93 (0.52, 1.67) 0.8146 1.27 (0.75, 2.12) 0.3740 
Current smoker 1.27 (0.65, 2.48) 0.4800 0.85 (0.40, 1.78) 0.6655 2.41 (1.16, 5.02) 0.0183 1.43 (0.68, 2.99) 0.3485 
Average number of 
alcoholic drinks in past 
year 
 
 
 
 
 
 
 
 
 
 
 
  
Poverall 
=0.6080 
   Rarely or never       Ref  
   ≤4 per week       1.08 (0.6, 1.94) 0.7885 
   5 per week to 1 daily       1.25 (0.63, 2.48) 0.5178 
   ≥ 2 daily       1.61 (0.78, 3.34) 0.2017 
AHO-Specific Risk Factor 
Cumulative dose of 
bleomycin, per 90,000 
IUError! Bookmark not defined. 
 
 
 
 
 
 
 
 1.36 (1.12, 1.65) 0.0016   
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Characteristic 
Adverse Health Outcome 
Tinnitus: Yes  
(Ref. = “No") 
Hearing Loss: Yes  
(Ref. = “No”) 
Raynaud Phenomenon: Yes 
(Ref. = “No”) 
Peripheral Neuropathy: Yes  
(Ref. = “No”)  
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Noise exposure  
Poverall 
=0.0189 
 
Poverall 
=0.0003 
    
None Ref  Ref      
Work-related noise 
only 
1.69 (1.02, 2.79) 0.0426 2.30 (1.32, 4.00) 0.0033 
    
Non-work-related noise 
only 
2.1 (1.03, 4.25) 0.0399 3.64 (1.70, 7.81) 0.0009 
    
Both        2.13 (1.22, 3.72) 0.0078 2.75 (1.49, 5.06) 0.0012     
Hypertension 1.08 (0.57, 2.02) 0.8175 2.40 (1.23, 4.67) 0.0101 1.13 (0.53, 2.39) 0.7529 1.23 (0.62, 2.43) 0.5468 
Cardiovascular disease 1.33 (0.57, 3.13) 0.5118 1.05 (0.41, 2.68) 0.9245 0.58 (0.18, 1.91) 0.3720 0.95 (0.36, 2.48) 0.9086 
Peripheral vascular 
disease 
    0.84 (0.22, 3.12) 0.7895 8.72 (2.41, 31.62) 0.0010 
Diabetes and on 
prescription medication 
    2.23 (0.47, 10.66) 0.3164 1.53 (0.37, 6.35) 0.5614 
Abbreviations:  AHO=adverse health outcome; BEP=bleomycin, etoposide, cisplatin; CI=Confidence Interval; EP=etoposide, cisplatin; VIP=etoposide, cisplatin, ifosfamide; 
VeIP=vinblastine, ifosfamide, cisplatin; IU=international unit 
 
a The standard BEP chemotherapy cycle that all of our patients received consists of bleomycin 30,000 IU days 1,8,15; etoposide 100 mg/m2 days 1 through 5; and cisplatin 20 
mg/m2 days 1 through 5. 
b Includes 32 patients with other cisplatin-based regimens: 11 participants with VIP and 1 with VeIP. Each standard VIP chemotherapy cycle that our patients received consists of 
etoposide 75 mg/m2 days 1 through 5, cisplatin 100 mg/m2 days 1through 5, and ifosfamide 1,200 mg/m2 days 1 through 5.      
c Reported results are calculated utilizing the statistical model that included the cumulative dose variable instead of the treatment group variable. Please refer to Supplementary 
Methods for details on statistical analysis modeling used.  
 Variable not included in the analysis for the indicated AHO. Please refer to Supplemental Methods. 
 
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/jncics/advance-article-abstract/doi/10.1093/jncics/pkz079/5583763 by IU
PU
I U
niversity Library user on 07 N
ovem
ber 2019
